Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
AECOM Q2 2026 Earnings Call - Record Backlog and Raised Guidance Driven by AI Wins and Defense Spending
AECOM delivered a second quarter of record-breaking execution, pushing adjusted EBITDA and adjusted EPS to new highs while expanding its backlog to an all-time level. The company raised full-year guid...
- Full-year adjusted EPS and EBITDA guidance raised to 14% and 7% growth respectively, marking the second upward revision this year.
- Record backlog reached new highs, driven by a 1.2x design book-to-burn ratio and robust win rates across the Americas and International segments.
- Americas design business drove 8% net service revenue growth, with segment adjusted operating margins expanding 60 basis points to 20%.
- +7 more takeaways
Biote Corp Q1 2026 Earnings Call - Supply Recall Drags Results as Management Bets on H2 Recovery
Biote Corp reported a sharp drop in first-quarter revenue and earnings, primarily due to a voluntary recall of bioidentical hormone pellets that cost the company $1.7 million in lost revenue and $1.5 ...
- Revenue fell 8.3% year-over-year to $44.9 million, with procedure revenue declining 13.2% to $31.3 million due to the voluntary product recall.
- The recall resulted in an estimated $1.7 million revenue impact and approximately $1.5 million in incremental costs, severely impacting Q1 gross margin which dropped to 68.9% from 74.3%.
- Net income was $2.7 million ($0.06 per diluted share), a significant decrease from $15.8 million ($0.37 per diluted share) in Q1 2025, partly due to smaller fair value gains on earn-out liabilities.
- +7 more takeaways
Legend Biotech Q1 2026 Earnings Call - CARVYKTI Sales Surge 62% as In Vivo Pipeline Gains Traction
Legend Biotech delivered a quarter of clear commercial momentum in Q1 2026, with CARVYKTI net trade sales reaching $597 million, up 62% year-over-year. The growth was broad-based, fueled by rapid expa...
- CARVYKTI net trade sales reached $597 million in Q1 2026, representing 62% year-over-year growth.
- U.S. sales grew 36% year-over-year, while ex-U.S. sales surged more than 200% year-over-year.
- Nearly 80% of CARVYKTI patients are treated in the community setting, with 41% of U.S. apheresis volume now in second and third lines.
- +7 more takeaways
Alliance Laundry Systems Q1 2026 Earnings Call - Raised Full-Year Guidance on Broad-Based Growth and Tariff Resilience
Alliance Laundry Systems delivered a robust first quarter of 2026, with revenue rising 10% year-over-year to $427 million and adjusted EBITDA climbing 9% to $109 million. The company raised its full-y...
- Revenue grew 10% year-over-year to $427 million, driven by 3% real unit volume growth and pricing actions.
- Adjusted EBITDA increased 9% to $109 million, with an adjusted EBITDA margin of 25.5%.
- Adjusted net income surged 85% year-over-year to $63 million, reflecting improved operating performance and lower interest expenses.
- +7 more takeaways
Arcutis Biotherapeutics Q1 2026 Earnings Call - ZORYVE Sales Surge 65% as Cash Flow Turns Positive
Arcutis Biotherapeutics delivered a robust first quarter in 2026, with ZORYVE net product revenues climbing 65% year-over-year to $105.4 million. The growth came despite heavy first seasonality, a pul...
- ZORYVE net product revenues reached $105.4 million in Q1 2026, a 65% increase year-over-year, driven by strong patient demand and improved gross-to-net from better formulary positioning.
- Arcutis achieved positive operating cash flow for the second consecutive quarter, generating $2.2 million in net cash from operations, a rare milestone for a growth-stage biotech.
- The company submitted a supplemental NDA to the FDA for ZORYVE cream 0.05% in infants aged 3 to 24 months with atopic dermatitis, based on rapid efficacy and safety data from the INTEGUMENT-INFANT trial.
- +7 more takeaways
Pangaea Logistics Solutions Q1 2026 Earnings Call - TCE Premiums and Chartered-In Fleet Expansion Drive Stronger Profitability
Pangaea Logistics Solutions delivered a solid Q1 2026, with adjusted EBITDA up $10M YoY to $25.2M, driven by TCE rates averaging 20% above market indices and a 14% increase in shipping days. The compa...
- Adjusted EBITDA grew $10M YoY to $25.2M, driven by 34% increase in TCE earnings.
- TCE rates averaged $15,252/day, a 20% premium over market indices for Panamax, Supramax, and Handysize vessels.
- Chartered-in fleet increased 54% YoY, allowing Pangaea to capture market opportunities without compromising flexibility.
- +7 more takeaways
Warner Bros. Discovery Q1 2026 Earnings Call - HBO Max Surpasses 140M Subscribers as Paramount Deal Nears
Warner Bros. Discovery delivered a quarter defined by relentless execution and a clear pivot toward scale. HBO Max crossed 140 million subscribers, driven by aggressive European rollouts and a content...
- HBO Max surpassed 140 million global subscribers in Q1 2026, exceeding guidance and accelerating toward a year-end target of 150 million.
- Streaming profitability has shifted dramatically, with the division moving from a $2 billion annual loss to $1.4 billion in profit last year and accelerating double-digit growth in Q1.
- Content performance is a standout driver, with The Pitt averaging over 20 million viewers per episode and A Knight of the Seven Kingdoms drawing 36 million viewers per episode.
- +7 more takeaways
Acumen Pharmaceuticals Q1 2026 Earnings Call - Sabirnetug ALTITUDE-AD Trial On Track For Late 2026 Readout With $128M Runway Into 2027
Acumen Pharmaceuticals advanced its sabirnetug program through the ALTITUDE-AD Phase II trial, maintaining high conversion rates into the 12-month open-label extension. The company expects top-line ef...
- Acumen Pharmaceuticals ended Q1 2026 with $128.4 million in cash and marketable securities, providing runway into early 2027.
- The ALTITUDE-AD Phase II trial for sabirnetug remains on track, with top-line results expected in late 2026.
- Sabirnetug targets toxic Abeta oligomers rather than amyloid plaques, aiming to differentiate from approved IgG1 antibodies.
- +7 more takeaways
OrganiGram Global Q2 FY2026 Earnings Call - Operational Hiccups in Vapes and IPRs Offset by Sanity Acquisition and Strong Canadian Flower Growth
OrganiGram Global reported a challenging Q2 FY2026, with net revenue declining 9% year-over-year to CAD 59.8 million due to operational execution issues in vapes and infused pre-rolls, alongside a bro...
- Net revenue declined 9% year-over-year to CAD 59.8 million in Q2 FY2026, primarily due to share erosion in vapes and infused pre-rolls caused by internal operational issues.
- The company maintained its position as Canada’s number one licensed producer by market share in Q2, despite a broader recreational market growth slowdown from 5% to 2.2%.
- Operational challenges in infused pre-rolls (IPRs) and vapes led to a 1.6 point share loss in pre-rolls and a 6.1 point year-over-year share decline in vapes, driven by quality inconsistencies and a mismatch in product potency formats.
- +11 more takeaways
Fastly Q1 2026 Earnings Call - Security and Compute Revenue Surge Drives Record Profitability
Fastly delivered a record-breaking first quarter of 2026, with revenue hitting $173 million and growing 20% year-over-year. The company's strategic pivot toward security and edge compute is paying off...
- Revenue reached $173 million, up 20% year-over-year, landing at the high end of guidance.
- Security revenue grew 47% year-over-year, now representing 22% of total revenue.
- Compute revenue surged 67% year-over-year, driven by edge AI workloads and agentic traffic.
- +7 more takeaways